Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06XEL
|
|||
| Former ID |
DCL000106
|
|||
| Drug Name |
DG051
|
|||
| Synonyms |
929916-05-2; DG-051; (S)-4-(2-((4-(4-chlorophenoxy)phenoxy)methyl)pyrrolidin-1-yl)butanoic acid; CHEMBL565789; 4-[(2s)-2-{[4-(4-Chlorophenoxy)phenoxy]methyl}pyrrolidin-1-Yl]butanoate; compound 20 [PMID: 19950900]; SCHEMBL989668; GTPL6548; PVCTYSQBVIGZRU-KRWDZBQOSA-N; BDBM50303649; ZINC34884331; AKOS030525381; 4-[(2S)-2-[4-(4-chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl]butanoic acid; 4-{(S)-2-[4-(4-Chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl}-butyric Acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myocardial infarction [ICD-11: BA41-BA43; ICD-9: 410] | Discontinued in Phase 2 | [1], [2] | |
| Company |
DeCODE genetics
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C21H25Cl2NO4
|
|||
| Canonical SMILES |
C1CC(N(C1)CCCC(=O)O)COC2=CC=C(C=C2)OC3=CC=C(C=C3)Cl.Cl
|
|||
| InChI |
1S/C21H24ClNO4.ClH/c22-16-5-7-19(8-6-16)27-20-11-9-18(10-12-20)26-15-17-3-1-13-23(17)14-2-4-21(24)25;/h5-12,17H,1-4,13-15H2,(H,24,25);1H/t17-;/m0./s1
|
|||
| InChIKey |
UCPVOTSNNAVKNE-LMOVPXPDSA-N
|
|||
| CAS Number |
CAS 929915-58-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukotriene A-4 hydrolase (LTA4H) | Target Info | Inhibitor | [3], [4] |
| BioCyc | Leukotriene biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Arachidonic acid metabolism | |||
| Eicosanoid Synthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6548). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024010) | |||
| REF 3 | BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8. | |||
| REF 4 | Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA. 2005 May 11;293(18):2245-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.